Table 1.
Patient Characteristics by Pathological Risk Category
| Characteristic | All Patients (N=36) | Patients with High-Risk Pathology (N=18) | Patients with Low/Int.-Risk Pathology (N=18) | p-value* | Diff (95% CI) |
|---|---|---|---|---|---|
| Age at enrollment (years) | |||||
| Median (range) | 60 (32–87) | 61.5 (37–87) | 58.5 (32–73) | 0.16 | 5 (−2 to 13) |
| Sex, N (%) | |||||
| Male | 26 (72) | 13 (72) | 13 (72) | 1.00 | 0 (−29 to 29) |
| Female | 10 (28) | 5 (28) | 5 (28) | ||
| Ethnicity, N(%) | |||||
| White | 28 (78) | 15 (83) | 13 (72) | 0.82 | 11 (−16 to 38) |
| Black | 6 (17) | 2 (11) | 4 (22) | −11 (−35 to 13) | |
| Asian | 2 (5) | 1 (6) | 1 (6) | 0 (−15 to 15) | |
| Smoking history, N (%) | |||||
| Ever | 31 (86) | 16 (89) | 15 (83) | 1.00 | 6 (−17 to 28) |
| Never | 5 (14) | 2 (11) | 3 (17) | ||
| Smoking pack-years | |||||
| Median (range) | 30 (0–80) | 30 (0–80) | 30 (0–80) | 0.79 | 0 (−15 to 10) |
| Alcohol use history, N(%) | |||||
| Ever | 23 (64) | 11 (61) | 12 (67) | 1.00 | −6 (−37 to 26) |
| Never | 13 (36) | 7 (39) | 6 (33) | ||
| ECOG Performance Status, N (%) | |||||
| 0 | 26 (72) | 16 (89) | 10 (56) | 0.06 | 33 (6 to 60) |
| 1 | 10 (28) | 2 (11) | 8 (44) | ||
| Tumor Site, N (%) | |||||
| Larynx/Hypopharynx | 10 (28) | 4 (22) | 6 (33) | 0.56 | −11 (−4 to 18) |
| Oral Cavity | 22 (61) | 11 (61) | 11 (61) | 0 (−32 to 32) | |
| Oropharynx | 4 (11) | 3 (17) | 1 (6) | 11 (−9 to 31) | |
| Clinical T stage, N (%) | |||||
| T1–T2 | 7 (19) | 4 (22) | 3 (17) | 0.59 | 5 (−20 to 31) |
| T3 | 4 (11) | 3 (17) | 1 (6) | 11 (−9 to 31) | |
| T4 | 25 (69) | 11 (61) | 14 (78) | −17 (−46 to 31) | |
| Clinical N stage. N (%) | |||||
| N0–N1 | 13 (36) | 2 (11) | 11 (61) | 0.005 | −50 (−77 to 23) |
| N2 | 21 (58) | 14 (78) | 7 (39) | 39 (9 to 68) | |
| N3 | 2 (6) | 2 (11) | 0 | 11 (−3 to 26) | |
| Clinical disease stage, N (%) | |||||
| III | 3 (8) | 0 | 3 (17) | 0.23 | −17 (−34 to 1) |
| IV | 33 (92) | 18 (100) | 15 (83) | ||
| Days First visit to surgery | |||||
| Median (range) | 33 (25–76) | 35 (25–76) | 33 (25–58) | 0.81 | 1 (−5 to 11) |
| Days Neoadjuvant pembrolizumab to surgery | |||||
| Median (range) | 16 (13–22) | 16 (13–22) | 18 (14–22) | 0.23 | −1 (−3 to 1) |
| Pathologic disease Stage, N (%) | |||||
| I–II | 3 (8) | 0 | 3 (17) | 1.00 | −17 (−34 to 1) |
| III | 6 (17) | 2 (11) | 4 (22) | −11 (−35 to 13) | |
| IVA–IVB | 27 (75) | 16 (89) | 11 (61) | 28 (10 to 55) | |
*
Wilcoxon signed rank test used for continuous variables; Fisher’s exact test used for categorical variables